Viviane A Lin1,2, Robin Lohse3, Michael T Madsen4, Tina Fransgaard4, Feza H Remzi5, Ismail Gögenur4. 1. Department of Surgery, Center for Surgical Science, Zealand University Hospital, Køge, Denmark. vial@regionsjaelland.dk. 2. Department of Surgery, Nordsjællands Hospital Hillerød, Hillerød, Denmark. vial@regionsjaelland.dk. 3. Department of Anesthesiology, Herlev Hospital, Herlev, Denmark. 4. Department of Surgery, Center for Surgical Science, Zealand University Hospital, Køge, Denmark. 5. Department of Surgery, Langone Medical Center, New York University, New York, NY, USA.
Abstract
BACKGROUND: Ulcerative colitis is associated with a higher risk for developing colorectal cancer. It is unknown whether this translates into a worse prognosis when malignancy occurs. The goal of this study was to compare long-term outcomes between patients with ulcerative colitis-associated colorectal cancer and sporadic colorectal cancer. METHODS: All patients who underwent surgery with curative intent for colorectal cancer in Denmark between January 2004 and June 2016 were included in the study. Patients diagnosed with ulcerative colitis were identified and matched 1:5 with patients with sporadic colorectal cancer using propensity score matching. The primary outcome was disease-free survival, with recurrence-free survival and all-cause mortality as secondary outcomes. In order to relate the results of the study to the existing literature, a systematic review with meta-analysis was conducted. RESULTS: A total of 1332 patients, 222 with ulcerative colitis and 1110 with sporadic colorectal cancer were included in the study. Disease-free survival was similar between the two groups with a hazards ratio (HR) 1.06 [95% confidence interval (CI) 0.85-1.32], as was recurrence-free survival HR 1.14 (95% CI 0.86-1.53) and all-cause mortality HR 1.15 (95% CI 0.89-1.48). The results of the systematic review identified seven other relevant studies. Meta-analysis showed a HR 1.67 (95% CI 0.61-4.56) for recurrence-free survival and HR 1.21 (95% CI 0.93-1.56) for all-cause mortality. CONCLUSIONS: There were no significant differences in long-term outcomes between ulcerative colitis-associated and sporadic colorectal cancer. However, the current results are limited by possible residual confounding and the meta-analysis by heterogeneity in confounding adjustment.
BACKGROUND: Ulcerative colitis is associated with a higher risk for developing colorectal cancer. It is unknown whether this translates into a worse prognosis when malignancy occurs. The goal of this study was to compare long-term outcomes between patients with ulcerative colitis-associated colorectal cancer and sporadic colorectal cancer. METHODS: All patients who underwent surgery with curative intent for colorectal cancer in Denmark between January 2004 and June 2016 were included in the study. Patients diagnosed with ulcerative colitis were identified and matched 1:5 with patients with sporadic colorectal cancer using propensity score matching. The primary outcome was disease-free survival, with recurrence-free survival and all-cause mortality as secondary outcomes. In order to relate the results of the study to the existing literature, a systematic review with meta-analysis was conducted. RESULTS: A total of 1332 patients, 222 with ulcerative colitis and 1110 with sporadic colorectal cancer were included in the study. Disease-free survival was similar between the two groups with a hazards ratio (HR) 1.06 [95% confidence interval (CI) 0.85-1.32], as was recurrence-free survival HR 1.14 (95% CI 0.86-1.53) and all-cause mortality HR 1.15 (95% CI 0.89-1.48). The results of the systematic review identified seven other relevant studies. Meta-analysis showed a HR 1.67 (95% CI 0.61-4.56) for recurrence-free survival and HR 1.21 (95% CI 0.93-1.56) for all-cause mortality. CONCLUSIONS: There were no significant differences in long-term outcomes between ulcerative colitis-associated and sporadic colorectal cancer. However, the current results are limited by possible residual confounding and the meta-analysis by heterogeneity in confounding adjustment.
Authors: Alexandra D Frolkis; Jonathan Dykeman; María E Negrón; Jennifer Debruyn; Nathalie Jette; Kirsten M Fiest; Talia Frolkis; Herman W Barkema; Kevin P Rioux; Remo Panaccione; Subrata Ghosh; Samuel Wiebe; Gilaad G Kaplan Journal: Gastroenterology Date: 2013-07-27 Impact factor: 22.682
Authors: Christine Leowardi; Marie-Luise Schneider; Ulf Hinz; Jonathan M Harnoss; Ignazio Tarantino; Felix Lasitschka; Alexis Ulrich; Markus W Büchler; Martina Kadmon Journal: Ann Surg Oncol Date: 2015-10-14 Impact factor: 5.344
Authors: Yoon Dae Han; Mahdi Hussain Al Bandar; Audrius Dulskas; Min Soo Cho; Hyuk Hur; Byung Soh Min; Kang Young Lee; Nam Kyu Kim Journal: BMC Surg Date: 2017-03-21 Impact factor: 2.102